Core Viewpoint - The research team has developed a portable microbial fuel cell using 3D printed living hydrogels, which has significant potential for applications in medical devices and sustainable energy supply [1][2]. Group 1: Technology and Innovation - The microbial fuel cell integrates bioelectrical stimulation devices to achieve precise regulation of electrophysiology and blood pressure, showcasing its application potential in disease treatment [1]. - The innovative 3D printed living hydrogel material, based on Shewanella bacteria, allows for the construction of complex structures and enhances mechanical strength and conductivity [2]. - The micro fuel cell, with a diameter of only 20mm, can output a stable voltage of 450mV and complete up to 10 cycles of "self-charging-discharge" [2]. Group 2: Performance and Advantages - The microbial fuel cell demonstrates a high bacterial survival rate of 97% after energy cycles, maintaining over 90% survival even after 100 hours of continuous operation, indicating excellent biocompatibility [2]. - The device avoids the use of scarce metals and toxic electrolytes found in traditional batteries, presenting significant environmental advantages [2]. - Although the energy density is currently at 0.008 watt-hours per liter and power density at 8.31 microwatts per square centimeter, it is sufficient for low-power devices [2]. Group 3: Application and Future Directions - The research targets instantaneous neural stimulation in precision medicine, with successful results in rat experiments showing significant blood pressure reduction [3][4]. - Future plans include developing implantable bio-batteries powered by human blood glucose, aiming for self-sustaining medical devices [4]. - The research reflects a cross-disciplinary innovation between synthetic biology and materials science, with promising applications in medical implants and environmental monitoring sensors [4].

Core Insights - A team from Colorado State University has successfully synthesized a "gene switch" that allows for the flexible activation or deactivation of key genetic traits in mature plants, marking a significant advancement in synthetic biology [1][2] - This research provides a theoretical and technical foundation for the programmable regulation of plant gene functions, enabling tailored design of plant characteristics for various applications [2] Group 1: Research Significance - The study represents a milestone in synthetic biology, enabling the creation of a genetic "switch" that functions similarly to an electronic circuit, allowing precise control over gene expression in response to external signals [1] - Prior to this, gene regulation technologies were limited to single-celled organisms, making this achievement in complex multicellular plants particularly noteworthy [1] Group 2: Applications and Future Prospects - The "gene circuit" developed can regulate different stages of plant life cycles and has potential applications in agriculture and materials science, such as enhancing drought resistance in crops or optimizing growth cycles for better yield and nutritional value [2] - Future advancements may include the use of machine learning to further optimize the design process of gene circuits, potentially automating operations and accelerating research and development [2] - This breakthrough technology is expected to contribute to food security and open new possibilities in environmental restoration and sustainable materials development, representing a significant step towards the "programming" of plant modifications [2]

Core Viewpoint - New Hope Dairy is focusing on innovation and consumer demand for fresh and diverse dairy products to navigate the challenges of a slowing market and declining consumption [1][2] Industry Overview - The domestic dairy industry is characterized by intense competition with a trend towards increased concentration among leading companies [2] - In 2024, China's total dairy production is projected to decline to 29.62 million tons, a decrease of 1.9% year-on-year, with liquid milk production experiencing its first drop in five years [2] - Per capita dairy consumption is expected to decrease by 5.6% year-on-year, indicating a shift in consumer behavior towards value and quality [2] Company Strategy - New Hope Dairy is committed to a "fresh strategy" that emphasizes product innovation across various categories, including fresh milk and beverages [3] - The company aims to enhance its competitive edge through the integration of AI and synthetic biology in its production processes [3] - New Hope Dairy's revenue for 2024 is projected at 10.665 billion yuan, a slight decrease of 2.93% year-on-year, while net profit is expected to rise by 24.8% to 538 million yuan [3] Growth Drivers - The company identifies three key growth drivers: high-end product development, deepening market penetration, and international expansion [4][5] - The "24-hour" fresh milk series and local market strategies are expected to contribute significantly to revenue growth, with high-end products seeing over 15% year-on-year revenue increase [5] - New Hope Dairy is also focusing on innovative distribution channels, including partnerships with major retailers and the establishment of fresh milk stores [5] Strategic Partnerships - New Hope Dairy has formed a strategic partnership with the Norwegian Gene Cow Breeding Association to introduce and cultivate Norwegian Red Cattle, enhancing its product offerings [6] - The company has already launched its first Norwegian Red Milk product, which has received positive market feedback [6]

Core Viewpoint - New Dairy Industry (002946) is addressing challenges in the dairy market, including sluggish consumption and growth slowdown, by focusing on innovation and new consumer demands for fresher, more diverse products [1] Group 1: Company Strategy - The chairman of New Dairy Industry, Xi Gang, emphasized the need to move beyond the "involution" of the existing market and seek solutions through innovation and growth [1] - The company will adhere to a "fresh strategy" as its core focus, aiming to build competitive barriers in the food and beverage sector through the integration of industry, AI, and synthetic biology [1] - New Dairy Industry plans to enhance emerging channels and user operations to drive fresh growth [1]

Core Insights - The Chinese beauty market is experiencing significant growth driven by ingredient-focused marketing, but there is a widening gap between consumer expectations and regulatory standards [1] - The complexity of new ingredients like bioactive peptides and plant extracts has outpaced existing national standards, leading to regulatory challenges [1][7] - Social media's promotion of high-concentration ingredients has resulted in consumer misconceptions about safety and efficacy, increasing the risk of health issues [1] Group 1: Medical Applications - Hyaluronic acid (HA) is primarily used for facial filling and shaping, addressing issues like wrinkles and volume loss, while collagen is crucial for skin firmness and elasticity [2][3] - HA provides immediate results and strong moisturizing effects, but its effects last only 6-12 months, requiring regular maintenance [4] - Collagen injections take longer to show results (1-2 weeks) but can stimulate the body's own collagen production, with effects lasting 6-18 months or longer [5] Group 2: Market Dynamics - HA dominates the aesthetic filler market due to lower production costs and widespread application, while collagen's market share is smaller but growing faster [8][9] - The production cost of collagen is 3-5 times higher than that of HA, which contributes to its higher retail price [8] - High prices for collagen may slow its market penetration, particularly in emerging markets, but some consumers view the cost as a reflection of quality [9] Group 3: Regulatory and Testing Standards - Current testing methods for HA include high-performance liquid chromatography (HPLC) and gel permeation chromatography (GPC), while collagen is tested using methods like the Kjeldahl method and BCA assay [6][7] - Regulatory focus is on purity, molecular weight distribution, and biological safety, with HA standards being more established than those for collagen [7] - The rapid development of new materials outpaces the evolution of traditional quality standards, posing challenges for regulatory compliance [7] Group 4: Future Trends - The next five years may see increased integration of HA and collagen in applications aimed at improving skin hydration and elasticity [10] - Innovations in synthetic biology could lead to breakthroughs in the use of collagen in tissue engineering and regenerative medicine [10] - As competition intensifies, prices for both HA and collagen products may decrease, driven by technological advancements and market entry of new players [11]

为助力生物基和生物制造产业高质量发展！ DT产业研究院 推出 《全球生物基产业月度报告》 系列 《生物基产业月度报告》 2025年5月（总第26期） 生物基产业月度报告 5分钟，掌握全球生物基产业最新情报和大厂动态，洞悉趋势，发现商机！ 最新5月期出炉，并已经通过邮箱发送至DT新材料新老客户，记得点击查看喔！ 同时，欢迎行业上下游同仁 免费领取 ！ 领取方式 ① ： 扫码下方二维码，提交信息后，即可下载报告（2份报告可一同下载）； 领取方式 ② ： www.bio-basedlink.net ，或点击文末 → 阅读原文 ↓ 领取方式 ③ ： 如果您是DT会员，请联系DT助手领取； ↓↓↓ Bio-based Industries Monthly Review Policy Release Capital Events Industry Dynamics Scientific Research Progress 总第26期 全球生物基和生物制造产业服务平台 https://www.bio-basedlink.net/ 皮德泰中研信息科技 ■ 新加料 目录 | 1. 政策发布 | | --- | | 1.1 国内 ...

于涛课题组长期致力于利用合成生物学方法，解决可持续制造、绿色能源的生物存储与粮食安全等重大问题。 在过去几十年里，大气中的CO2通过热化学、电化 学、光化学以及一些耦合策略转化为简单的低碳化合物（C1-3）已经取得了巨大进展 。然而，通过这些平台生产复杂的化合物是极其困难的。而以这些平台合成 的低碳化合物为底物，可通过微生物细胞工厂转化生产高碳化合物。 于涛课题组的前期工作（ Nature Catalysis | 二氧化碳还原合成葡萄糖和脂肪酸 ）表明，通过电化学偶联微生物细胞工厂，成功实现了将CO2变成葡萄糖和脂肪酸 （"空气变粮油"），这为将CO2可持续转变成糖衍生食品和化学品提供了一种可行的、高效的方法，其具有更低的成本、更快的速度和更高的生产能力，该成果入 选2022年由两院院士评选出的"中国十大科技进展新闻"。 # SynBio团队 | 深圳先进院于涛 随后，于涛课题组又成功的在酵母细胞内构建了一个合成能量系统（细胞"双引擎"设计），可以支持细胞生长并助力脂肪酸高效合成（Nature Metabolism | 理性设计构建合成能量系统双引擎助力细胞工厂）。同时，课题组还利用合成生物学和代谢工程手段， ...

【SynBioCon】 获悉，近日，关于 百开盛（江苏）生物科技有限公司 新建绿色生物合成产业化项目在相关网站公示。 项目概况 项目名称：百开盛（江苏）生物科技有限公司公司新建绿色生物合成产业化项目 建设性质：新建 建设单位：百开盛（江苏）生物科技有限公司 投资总额：项目总投资12000万元，环保投资613万元； 建设地点：江苏省连云港市灌南县经济开发区珠海西路8号； 项目类别：第十一食品制造业-第24其他食品制造149； 国民经济代码：C1495食品及饲料添加剂制造及C1492保健食品制造； # 项目进展 | 百开盛生物 占地面积：29597平方米（44.39亩） 建设计划：本项目不分期，计划2025年6月开工，2025年12月完工 建设内容：本项目建设自动化柔性发酵生产线，产品后处理、纯化及灌装（包装）等生产线，同时配套建设仓储车间等，通 过生物合成等工艺，年生产角鲨烯180吨/年，麦角硫因10吨/年，瑞鲍迪苷M50吨/年，瓦伦烯20吨/年及依克多因40吨/年。 产品方案及应用 | 序号 | 车间或生产线 | 产品名称 | 设计生产能 力(t/a) | 生产批 次 | 批次产量 (t) | 年运行时 数( ...

华恒生物688639 时间: 2025年6月10日星期二 68.90分综合得分 较强 趋势方向 主力成本分析 33.71 元 当日主力成本 33.89 元 5日主力成本 31.06 元 20日主力成本 29.77 元 60日主力成本 周期内涨跌停 过去一年内该股 涨停 0次 短期压力位 次 32.60 短期支撑位 34.13 北向资金数据 持股量179.43万股 占流通比0.78% 昨日净买入0.94万股 昨日增仓比0.004% 5日增仓比0.03% 20日增仓比0.174% 跌停 0 技术面分析 34.13 中期压力位 28.05 中期支撑位 目前短线趋势不慎明朗，静待主力资金选择方向； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 ★光脚阴线★ 下跌信号 ★长上影★ 表明行情上档压力沉重,升势受阻 ★倒转锤头★ 可能见底回升 资金流数据 每股收益0.2元 营业利润0.55亿元 市盈率--- 销售毛利率24.308% 净利润49,138,959.43元 2025年6月10日星期二 68.90 较强 33.71； 33.89； 31.06； 29.77； 2025年06月10日的资金流向数据方面 主力 ...

Policy Developments - The Central Committee and State Council issued an opinion to improve the adjustment mechanism for the basic medical insurance drug catalog and to establish an innovative drug catalog for commercial health insurance [2] - The opinion aims to promote the sharing of high-quality medical resources and enhance the capacity of grassroots medical institutions [2] - The commercial health insurance sector is becoming a crucial lever for the high-quality development of commercial health insurance, helping to address the payment challenges for innovative drugs [3] Medical Device Approvals - DaAn Gene obtained a medical device registration certificate for six nucleic acid test kits for respiratory pathogens, expanding its product portfolio [5] - BGI Innovation received a medical device registration certificate for a human papillomavirus genotyping test kit, classified as Class III [6] - Shanghai Pharmaceuticals received approval for the production of Formoterol Fumarate inhalation solution, which is used for the maintenance treatment of chronic obstructive pulmonary disease [7] Corporate Transactions - Pilin Bio announced the resumption of trading after China National Pharmaceutical Group acquired 21.03% of its shares, changing the controlling shareholder [8] - China General Nuclear Power Corporation plans to inject 500 million yuan into its subsidiary for proton medical research and development [9] - Zhonghui Pharmaceutical completed two rounds of financing totaling nearly 50 million yuan, which will be used for the construction of a hollow microneedle medical device production base [10] Industry Developments - Dongxing Medical's subsidiary signed two contracts with Shanghai Jiao Tong University for synthetic biology technology development, totaling 6 million yuan [11] Regulatory Alerts - Huahai Pharmaceutical received a warning letter from the FDA regarding its production facility, which may affect future ANDA applications but will not significantly impact current performance [12]